Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended March 31, 2026
Business Overview: Supernus is a biopharmaceutical company focused on central nervous system (CNS) diseases. Key commercial products include Qelbree (ADHD), GOCOVRI (Parkinson's), ONAPGO (Parkinson's), and ZURZUVAE (Postpartum Depression). The company operates in a single segment and recently integrated Sage Therapeutics, Inc. (acquired July 2025) into its operations.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $207,705 | $149,824 |
| Net Product Sales | $150,753 | $141,988 |
| Collaboration Revenue (ZURZUVAE) | $27,643 | $0 |
| Net Loss | $(2,293) | $(11,827) |
| Operating Loss | $(8,332) | $(10,256) |
| Cash from Operating Activities | $66,524 | $30,599 |
| Cash and Cash Equivalents (End of Period) | $184,869 | $115,848 |
| Total Assets | $1,500,725 | $1,452,648 |
| Debt | $0 | $0 |
Note: The company has no outstanding debt under its $150 million credit line as of March 31, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 39% to $207.7 million, driven by the inclusion of ZURZUVAE collaboration revenue ($27.6 million) and the launch of ONAPGO ($8.4 million). Net product sales grew 6% to $150.8 million.
- Product Performance:
- Qelbree: Sales increased 20% to $77.8 million.
- GOCOVRI: Sales increased 15% to $35.2 million.
- Declines: APOKYN sales dropped 48% due to lower volume; Trokendi XR and Oxtellar XR declined 26% and 27% respectively due to generic erosion.
- Profitability: Net loss narrowed significantly to $2.3 million from $11.8 million in Q1 2025. This improvement was aided by a $3.7 million income tax benefit (vs. $6.0 million expense in prior year) and reduced contingent consideration loss ($2.4 million vs. $7.7 million).
- Expenses: Selling, General, and Administrative (SG&A) expenses rose 39% to $125.2 million, primarily due to ONAPGO launch costs and shared Biogen collaboration expenses. R&D expenses increased 46% to $39.4 million, driven by SPN-817 clinical costs and a $10.0 million payment to former Biscayne security holders.
Outlook, Risks, and Contingencies
- Supply Chain: ONAPGO faced supplier constraints in late 2025 but resumed new patient initiation in February 2026. A second supplier is expected to begin supply in 2027 pending regulatory approval.
- Contingent Consideration: A $33.4 million milestone related to the commercial launch of ZURZUVAE in Japan was met and reclassified to current liabilities. Remaining potential contingent payments from the Sage acquisition range from $0 to $201 million.
- Legal Proceedings:
- Patent Litigation: Multiple consolidated lawsuits against generic manufacturers (Appco, Apotex, Aurobindo, etc.) regarding Qelbree patents. Automatic stays prevent FDA approval of generics until October 2028.
- Sage Litigation: Ongoing securities class action, SEC investigation, and derivative litigation related to the Sage acquisition and zuranolone NDA. The company is unable to estimate potential losses.
- Antitrust: APOKYN antitrust lawsuit trial is scheduled for January 2027.
- Liquidity: Management believes cash, cash equivalents, and marketable securities ($384.2 million) are sufficient to fund operations for the next 12 months and beyond.
Key Investor Verification Points
- ONAPGO Supply Stability: Verify the timeline for the second supplier's regulatory approval and the impact of single-source dependency on future sales.
- Generic Erosion: Monitor the trajectory of sales declines for Trokendi XR and Oxtellar XR as generic competition matures.
- Legal Exposure: Assess the potential financial impact of the consolidated Qelbree patent litigation and the unresolved Sage-related securities/derivative lawsuits.
- Contingent Liabilities: Track the achievement of remaining milestones for the Sage acquisition, which could trigger up to $201 million in additional payments.
- SPN-820 Development: Review the results of the ongoing Phase 2b study for SPN-820 (depression), given the previous Phase 2b failure in treatment-resistant depression.